X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Mitchga (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody, which is approved for the treatment of atopic dermatitis and prurigo nodularis.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: Mitchga
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The agreement aims to develop and commercialize AOB's topical biologic B244, currently preparing for global Phase 3 clinical trials, a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).
Lead Product(s): B244
Therapeutic Area: Dermatology Product Name: B244
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: AOBiome Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2024
Details:
The collaboration aims to develop and commercialize EVO756 in Japan. Evommune’s MRGPRX2 antagonist, is an investigational therapy with the potential to be a first-in-class oral treatment for a variety of mast cell mediated disease.
Lead Product(s): EVO756
Therapeutic Area: Immunology Product Name: EVO756
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Evommune
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
Mitchga (Nemolizumab) is the first antibody drug targeting IL-31 receptor A, for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: Mitchga
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
BX005 is currently in the final stages of GMP production. The Company continues to expect the first data readout from its Phase 1/2 proof-of-concept trial evaluating the safety and efficacy.
Lead Product(s): BX005
Therapeutic Area: Dermatology Product Name: BX005
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BiomX
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan.
Lead Product(s): Ruxolitinib Phosphate
Therapeutic Area: Dermatology Product Name: Opzelura
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Incyte Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 28, 2022
Details:
The approval of Mitchga, the first antibody-drug targeting interleukin-31, is based on the results from a Japanese phase III clinical study in patients with moderate to severe AD who are older than 13 years old and are tolerant to existing treatments.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: Mitchga
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
QBREXZA (Rapifort® Wipes 2.5%), is a topical product approved by the U.S. Food and Drug Administration for treatment of primary axillary hyperhidrosis in adult and pediatric populations (ages nine-years and older) and is self-administered by patients.
Lead Product(s): Glycopyrronium Tosylate
Therapeutic Area: Dermatology Product Name: Rapifort Wipes
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Journey Medical Corporation
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 11, 2022
Details:
Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study of atopic dermatitis product candidate, BX005, in Japan.
Lead Product(s): BX005
Therapeutic Area: Dermatology Product Name: BX005
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: BiomX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
